No Data
No Data
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
OtechBio (688606.SH) released its performance for the first half of the year, with a net income of 0.124 billion yuan, a year-on-year increase of 74.03%.
Aotec Biopharmaceuticals (688606.SH) released its semi-annual report for 2024, with revenue of 0.397 billion yuan...
Aotecar Biology (688606.SH): The net income in the first half of the year was 0.12 billion yuan, a year-on-year increase of 74.03%.
On August 30th, Outei Biological (688606.SH) released its semi-annual report. The company's revenue in the first half of the year was 396.5034 million yuan, an increase of 2.23% compared to the same period last year. Among them, the revenue from infectious disease testing products was 166.2669 million yuan, an increase of 31.10% compared to the same period last year. The revenue from drug and substance abuse testing products was 102.3142 million yuan, an increase of 9.25% compared to the same period last year. The revenue from tumor marker testing products and myocardial marker testing products was 20.264 million yuan, an increase of 26.55% compared to the same period last year. The revenue from women's health testing products was...
Aotai Biological (688606.SH): Currently, it has obtained the European Union CE certification for monkeypox products.
On August 14th, Gelunhui reported that Autobio Diagnostics (688606.SH) has obtained the EU CE certification for its monkeypox products and can be sold in EU countries and countries that recognize the EU CE certification. The company will continue to closely monitor the development of monkeypox-related epidemics in overseas markets. Please continue to follow the company's periodic reports for information on the company's operating performance. The company will release its 2024 semi-annual report on August 31, 2024.
Is The Market Rewarding Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
No Data